These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 20589874)
1. Brain interstitial nociceptin/orphanin FQ levels are elevated in Parkinson's disease. Marti M; Sarubbo S; Latini F; Cavallo M; Eleopra R; Biguzzi S; Lettieri C; Conti C; Simonato M; Zucchini S; Quatrale R; Sensi M; Candeletti S; Romualdi P; Morari M Mov Disord; 2010 Aug; 25(11):1723-32. PubMed ID: 20589874 [TBL] [Abstract][Full Text] [Related]
2. Endogenous nociceptin/orphanin FQ (N/OFQ) contributes to haloperidol-induced changes of nigral amino acid transmission and parkinsonism: a combined microdialysis and behavioral study in naïve and nociceptin/orphanin FQ receptor knockout mice. Mabrouk OS; Marti M; Morari M Neuroscience; 2010 Mar; 166(1):40-8. PubMed ID: 20006677 [TBL] [Abstract][Full Text] [Related]
3. Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. Marti M; Mela F; Fantin M; Zucchini S; Brown JM; Witta J; Di Benedetto M; Buzas B; Reinscheid RK; Salvadori S; Guerrini R; Romualdi P; Candeletti S; Simonato M; Cox BM; Morari M J Neurosci; 2005 Oct; 25(42):9591-601. PubMed ID: 16237164 [TBL] [Abstract][Full Text] [Related]
5. Blockade of nociceptin/orphanin FQ transmission in rat substantia nigra reverses haloperidol-induced akinesia and normalizes nigral glutamate release. Marti M; Mela F; Guerrini R; Calò G; Bianchi C; Morari M J Neurochem; 2004 Dec; 91(6):1501-4. PubMed ID: 15584926 [TBL] [Abstract][Full Text] [Related]
6. Dopamine-nociceptin/orphanin FQ interactions in the substantia nigra reticulata of hemiparkinsonian rats: involvement of D2/D3 receptors and impact on nigro-thalamic neurons and motor activity. Volta M; Viaro R; Trapella C; Marti M; Morari M Exp Neurol; 2011 Mar; 228(1):126-37. PubMed ID: 21215744 [TBL] [Abstract][Full Text] [Related]
8. MPTP treatment increases expression of pre-pro-nociceptin/orphanin FQ mRNA in a subset of substantia nigra reticulata neurons. Gouty S; Brown JM; Rosenberger J; Cox BM Neuroscience; 2010 Aug; 169(1):269-78. PubMed ID: 20417255 [TBL] [Abstract][Full Text] [Related]
9. Alterations of N/OFQ and NOP receptor gene expression in the substantia nigra and caudate putamen of MPP+ and 6-OHDA lesioned rats. Di Benedetto M; Cavina C; D'Addario C; Leoni G; Candeletti S; Cox BM; Romualdi P Neuropharmacology; 2009 Mar; 56(4):761-7. PubMed ID: 19162046 [TBL] [Abstract][Full Text] [Related]
10. Stimulation of delta opioid receptors located in substantia nigra reticulata but not globus pallidus or striatum restores motor activity in 6-hydroxydopamine lesioned rats: new insights into the role of delta receptors in parkinsonism. Mabrouk OS; Volta M; Marti M; Morari M J Neurochem; 2008 Dec; 107(6):1647-59. PubMed ID: 19094058 [TBL] [Abstract][Full Text] [Related]
11. The nociceptin/orphanin FQ receptor antagonist J-113397 and L-DOPA additively attenuate experimental parkinsonism through overinhibition of the nigrothalamic pathway. Marti M; Trapella C; Viaro R; Morari M J Neurosci; 2007 Feb; 27(6):1297-307. PubMed ID: 17287504 [TBL] [Abstract][Full Text] [Related]
12. Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism. Fantin M; Auberson YP; Morari M J Neurochem; 2008 Jul; 106(2):957-68. PubMed ID: 18435828 [TBL] [Abstract][Full Text] [Related]
13. Stimulation of δ opioid receptor and blockade of nociceptin/orphanin FQ receptor synergistically attenuate parkinsonism. Mabrouk OS; Viaro R; Volta M; Ledonne A; Mercuri N; Morari M J Neurosci; 2014 Sep; 34(39):12953-62. PubMed ID: 25253844 [TBL] [Abstract][Full Text] [Related]
14. Kainate seizures increase nociceptin/orphanin FQ release in the rat hippocampus and thalamus: a microdialysis study. Aparicio LC; Candeletti S; Binaschi A; Mazzuferi M; Mantovani S; Di Benedetto M; Landuzzi D; Lopetuso G; Romualdi P; Simonato M J Neurochem; 2004 Oct; 91(1):30-7. PubMed ID: 15379884 [TBL] [Abstract][Full Text] [Related]
15. Nociceptin/Orphanin FQ Inhibits the Survival and Axon Growth of Midbrain Dopaminergic Neurons Through a p38-MAPK Dependent Mechanism. Collins LM; Dal Bo G; Calcagno M; Monzón-Sandoval J; Sullivan AM; Gutierrez H; Morari M; O'Keeffe GW Mol Neurobiol; 2016 Dec; 53(10):7284-7297. PubMed ID: 26687234 [TBL] [Abstract][Full Text] [Related]
16. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease. González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990 [TBL] [Abstract][Full Text] [Related]
17. The novel nociceptin/orphanin FQ receptor antagonist Trap-101 alleviates experimental parkinsonism through inhibition of the nigro-thalamic pathway: positive interaction with L-DOPA. Marti M; Trapella C; Morari M J Neurochem; 2008 Dec; 107(6):1683-96. PubMed ID: 19014386 [TBL] [Abstract][Full Text] [Related]
18. Autoradiographic localization of (125)I[Tyr(14)]orphanin FQ/nociceptin and (125)I[Tyr(10)]orphanin FQ/nociceptin(1-11) binding sites in rat brain. Letchworth SR; Mathis JP; Rossi GC; Bodnar RJ; Pasternak GW J Comp Neurol; 2000 Jul; 423(2):319-29. PubMed ID: 10867661 [TBL] [Abstract][Full Text] [Related]
19. Further evidence for an involvement of nociceptin/orphanin FQ in the pathophysiology of Parkinson's disease: a behavioral and neurochemical study in reserpinized mice. Volta M; Mabrouk OS; Bido S; Marti M; Morari M J Neurochem; 2010 Dec; 115(6):1543-55. PubMed ID: 20950413 [TBL] [Abstract][Full Text] [Related]
20. Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats. Narayanan S; Lam H; Carroll FI; Lutfy K J Psychiatry Neurosci; 2004 Mar; 29(2):116-23. PubMed ID: 15069465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]